Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Two- and 6-minute walk tests assess walking capability equally in neuromuscular diseases

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Fat oxidation is impaired during exercise in lipin-1 deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Declining malformation rates with changed antiepileptic drug prescribing: An observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  4. Clinical spectrum of STX1B-related epileptic disorders

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Electromagnetic source imaging in presurgical workup of patients with epilepsy: A prospective study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hydroxylated Long-Chain Acylcarnitines are Biomarkers of Mitochondrial Myopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. MSTO1 mutations cause mtDNA depletion, manifesting as muscular dystrophy with cerebellar involvement

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Fat oxidation is impaired during exercise in lipin-1 deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: This methodologic study investigates if the 2-minute walk test (2MWT) can be a valid alternative to the 6-minute walk test (6MWT) to describe walking capability in patients with neuromuscular diseases.

METHODS: Patients (n = 115) with different neuromuscular diseases were invited to participate on 2 test days, each consisting of 1 2MWT and 1 6MWT separated by a minimum 30-minute period of rest. The order of the walk tests was randomly assigned via sealed envelopes. A group of 38 healthy controls completed 1 6MWT.

RESULTS: The mean walking distance for the 2MWT was 142.8 meters and for the 6MWT 405.3 meters. The distance walked in the 2MWT was highly correlated to the distance walked in the 6MWT (r = 0.99, p < 0.001). There was a significant decrease in walking speed from the first to last minute in the 6MWT, both among patients and healthy controls, which was not evident in the 2MWT. Results were consistent across diagnoses and levels of disease severity.

CONCLUSION: The 2MWT is a potential alternative to the 6MWT to describe walking capability among patients with neuromuscular diseases during clinical trials.

Original languageEnglish
JournalNeurology
Volume86
Issue number5
Pages (from-to)442-445
Number of pages4
ISSN0028-3878
DOIs
Publication statusPublished - 2 Feb 2016

    Research areas

  • Adult, Aged, Aged, 80 and over, Exercise Test, Female, Humans, Male, Middle Aged, Muscle Strength, Muscle Weakness, Neuromuscular Diseases, Time Factors, Walking, Young Adult, Journal Article

ID: 49288045